share_log

Baird:下调Biomarin Pharmaceutical(BMRN.US)评级,由优于大市调整至中性评级, 目标价由104.00美元调整至72.00美元。

Zhitong Finance ·  May 17 05:25

Baird:下调Biomarin Pharmaceutical(BMRN.US)评级,由优于大市调整至中性评级, 目标价由104.00美元调整至72.00美元。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment